Back
LYFE SCIENCES
Project: HERA
NM_024675.3:c.3049G>A
p.Ala1017Thr  ·  PALB2
Starting
Initialising…
0%
Legacy Engine
Processing…
Classification rationale
1

NM_024675.3:c.3049G>A (p.Ala1017Thr) is a missense variant in PALB2, a gene for which loss of function is an established mechanism of PALB2-related cancer predisposition (autosomal dominant) and Fanconi anemia complementation group N (autosomal recessive).

cspec ↗
2

This variant has been classified as a Variant of Uncertain Significance by the ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Variant Curation Expert Panel (ClinVar Variation ID: 830187) and by seven clinical laboratories.

clinvar ↗
3

In gnomAD v4.1, this variant is present at an overall allele frequency of 0.000081% (13/1,614,106 alleles; grpmax FAF=0.0075%), with the highest frequency in the South Asian population (0.0132%; 12/91,078 alleles). The gnomAD v2.1 frequency is 0.00040% (1/251,448 alleles).

gnomad_v2 ↗ gnomad_v4 ↗
4

SpliceAI predicts no splicing impact (max delta score = 0.00). REVEL score is 0.202 and BayesDel score is -0.306, both in ranges consistent with a benign computational prediction, though in silico predictors are not used for missense variants under the PALB2 VCEP framework.

spliceai ↗
5

Under the PALB2 VCEP v1.2.0 framework, BP1 (Supporting) is met because all PALB2 missense variants are assigned BP1 at Supporting strength, given the very low rate of functional missense variants in PALB2. No other criteria are met under this VCEP framework.

cspec ↗
6

The PM2 (Supporting) criterion is not met because the variant's gnomAD v4.1 frequency (0.00081%) exceeds the VCEP threshold of ≤0.000333%. Population frequency criteria BA1 (>0.1%) and BS1 (>0.01%) are also not met, as the grpmax FAF (0.0075%) falls below both thresholds.

gnomad_v4 ↗ cspec ↗
7

PS4 is not met; although this variant has been observed in 3 cancer cases in a case-control study (Momozawa et al. 2018), no formal odds ratio or statistical significance test meeting the VCEP threshold (OR≥3, p≤0.05) has been computed for this individual variant.

cspec ↗
8

Many ACMG/AMP criteria are not applicable under the PALB2 VCEP for missense variants, including PVS1 (not a null variant), PS1/PP3/BP4 (missense excluded), PM1 (missense mechanism not confirmed), PM5 (truncation/splice only), PP2 (missense mechanism not confirmed), and PS3/BS3 (not used in this VCEP).

cspec ↗
9

Several criteria (PP1, BS2, BS4) remain not assessed due to absence of published co-segregation, healthy adult proband, or non-segregation data for this specific variant.

cspec ↗
10

With only BP1_Supporting met and no pathogenic criteria met, this variant does not satisfy the criteria for Likely Benign (requires ≥2 benign supporting or 1 strong benign + ≥1 supporting benign). The variant remains classified as a Variant of Uncertain Significance (VUS) under the PALB2 VCEP v1.2.0 framework.

cspec ↗ clinvar ↗
Applied criteria
Met
Not met
Not assessed
N/A
Very strong
Strong
Moderate
Supporting
Pathogenic evidence
PVS
PVS1
PS
PS1
PS2
PS3
PS4
PM
PM1
PM2
PM3
PM4
PM5
PM6
PP
PP1
PP2
PP3
PP4
PP5
Benign evidence
BA
BA1
BS
BS1
BS2
BS3
BS4
BP
BP1
BP2
BP3
BP4
BP5
BP6
BP7
PVS1
Rationale
Select a criterion to inspect its explanation.
Evidence used
Gaps remaining
Rule
Publications
Research and evidence
gnomAD v2.1 evidence
v2.1
gnomAD v4.1 evidence
v4.1
01
Population
gnomAD v2.1This variant is present in gnomAD v2.1 (AF= 3.97697e-06; MAF= 0.00040%, 1/251448 alleles, homozygotes = 0) and has highest observed frequency in the South Asian population (AF= 3.26627e-05; MAF= 0.00327%, 1/30616 alleles, homozygotes = 0).
gnomAD v4.1This variant is present in gnomAD v4.1 (AF= 8.05399e-06; MAF= 0.00081%, 13/1614106 alleles, homozygotes = 0) and has highest observed frequency in the South Asian population (AF= 0.000131755; MAF= 0.01318%, 12/91078 alleles, homozygotes = 0); grpmax FAF= 7.506e-05.
gnomAD CanadaAvailable
ClinVar evidence
02
ClinVar
This variant has been reported in ClinVar as Uncertain significance (7 clinical laboratories) and as Uncertain Significance by ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Variant Curation Expert Panel, ClinGen (expert panel). (ClinVarID = 830187)
Functional evidence
03
Functional
OncoKB: Unknown Oncogenic Effect
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. PALB2, a scaffolding protein involved in DNA repair, is altered in various cancers.
In silico evidence
04
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.202. BayesDel score = -0.305671.
COSMIC evidence
05
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
Cancer hotspots evidence
06
Cancer hotspots Not found
This variant does not lie in a statistically significant hotspot.